BioLife Solutions, Inc. (BLFS) AI Stock Analysis

BioLife Solutions, Inc. is a developer, manufacturer, and supplier of bioproduction tools and services catering to the cell and gene therapy industry worldwide. Headquartered in Bothell, Washington, the company provides essential products used in basic and applied research as well as commercial biologic manufacturing. Proprietary offerings include biopreservation media such as HypoThermosol FRS and CryoStor, along with the ThawSTAR automated thawing product line. Its portfolio also features evo cloud-connected shipping containers for temperature-sensitive biologics and cryogenic equipment, including liquid nitrogen laboratory freezers. It sells products via direct sales and third-party distributors across North America, Europe, the Middle East, and Africa.

Annual revenue grew from $68.0M in FY2023 to $82.3M in FY2024 and reached $96.2M in FY2025, reflecting a 17.0% growth rate in FY2025. Over the 5-year span from FY2020 to FY2025, revenue grew at a CAGR of 14.9%. Net losses narrowed from -$139.8M in FY2022 to -$68.0M in FY2023, -$20.2M in FY2024, and -$12.1M in FY2025. Gross margin expanded from 31.1% in FY2021 to 64.6% in FY2025. For the trailing twelve months, revenue was $106.7M with a 54.4% profit margin. In the quarter ended June 30, 2026, revenue increased 21.5% year-over-year, while quarterly earnings declined 13.9%.

As of June 30, 2026, BioLife Solutions held $82.4M in cash and short-term investments against $15.7M in total debt, yielding a net cash position of $66.7M. The balance sheet shows a current ratio of 9.69 and a debt-to-equity ratio of 0.04 across $420.0M in shareholders' equity. Operating cash flow improved to $20.1M in FY2025, yielding free cash flow of $416,000 after capital expenditures of $19.7M. Over five years, the company's share count increased 18.3%.

BioLife Solutions trades at a trailing P/E of 39.0x and a forward P/E of 238.1x, compared to the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its price-to-sales ratio stands at 17.7x versus the peer median of 4.1x, and its EV-to-EBITDA is 343.6x compared to the peer median of 12.0x. Over the past year, the stock gained 46.8%, outperforming the S&P 500 (SPY) return of 17.4%. However, its 5-year return of -5.4% lagged the S&P 500 return of 89.4%.

The consensus mean price target is $31.00, representing a -19.7% decline from the last close of $38.61 on October 7, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $115.3M and an EPS of $0.25, indicating 91.9% EPS growth. BioLife Solutions has beaten EPS estimates in each of the last 4 quarters. The next earnings date is scheduled for November 5, 2026.

This page is an AI-written research summary of BioLife Solutions, Inc. (BLFS). The text was generated on October 30, 2026 from Quotelinks data as of October 7, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BLFS income statement, BLFS balance sheet, BLFS key metrics, BLFS analyst forecast, BLFS chart. See the BLFS stock overview for the latest quote and news.